Mechanisms of multidrug resistance in cancer chemotherapy

K Bukowski, M Kciuk, R Kontek - International journal of molecular …, 2020 - mdpi.com
Cancer is one of the main causes of death worldwide. Despite the significant development of
methods of cancer healing during the past decades, chemotherapy still remains the main …

DNA repair pathways and cisplatin resistance: an intimate relationship

CRR Rocha, MM Silva, A Quinet, JB Cabral-Neto… - Clinics, 2018 - SciELO Brasil
The main goal of chemotherapeutic drugs is to induce massive cell death in tumors.
Cisplatin is an antitumor drug widely used to treat several types of cancer. Despite its …

DNA damage checkpoint kinases in cancer

HL Smith, H Southgate, DA Tweddle… - Expert reviews in …, 2020 - cambridge.org
DNA damage response (DDR) pathway prevents high level endogenous and environmental
DNA damage being replicated and passed on to the next generation of cells via an …

ATM mutations in cancer: therapeutic implications

M Choi, T Kipps, R Kurzrock - Molecular cancer therapeutics, 2016 - aacrjournals.org
Activation of checkpoint arrest and homologous DNA repair are necessary for maintenance
of genomic integrity during DNA replication. Germ-line mutations of the ataxia telangiectasia …

Sulfoximines from a medicinal chemist's perspective: physicochemical and in vitro parameters relevant for drug discovery

M Frings, C Bolm, A Blum, C Gnamm - European journal of medicinal …, 2017 - Elsevier
Sulfoximines, sulfondiimides and sulfonimidamides are fascinating but not yet fully explored
variants of the common sulfone or sulfonamide motif. In this study, we report the …

Targeting ATR in cancer

E Lecona, O Fernandez-Capetillo - Nature Reviews Cancer, 2018 - nature.com
The chemical treatment of cancer started with the realization that DNA damaging agents
such as mustard gas present notable antitumoural properties. Consequently, early drug …

ATR/CHK1 inhibitors and cancer therapy

Z Qiu, NL Oleinick, J Zhang - Radiotherapy and Oncology, 2018 - Elsevier
The cell cycle checkpoint proteins ataxia-telangiectasia-mutated-and-Rad3-related kinase
(ATR) and its major downstream effector checkpoint kinase 1 (CHK1) prevent the entry of …

[HTML][HTML] DNA repair targeted therapy: The past or future of cancer treatment?

NS Gavande, PS VanderVere-Carozza… - Pharmacology & …, 2016 - Elsevier
The repair of DNA damage is a complex process that relies on particular pathways to
remedy specific types of damage to DNA. The range of insults to DNA includes small …

ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib

Z Wilson, R Odedra, Y Wallez, PWG Wijnhoven… - Cancer …, 2022 - aacrjournals.org
AZD6738 (ceralasertib) is a potent and selective orally bioavailable inhibitor of ataxia
telangiectasia and Rad3-related (ATR) kinase. ATR is activated in response to stalled DNA …

Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent

KM Foote, JWM Nissink, T McGuire, P Turner… - 2018 - ACS Publications
The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the
DNA-damage response and the apical kinase which orchestrates the cellular processes that …